---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-015753"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:18:30.309787+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioCardia announces FDA alignment on Helix catheter clearance pathways; no safety concerns

## Summary
- FDA agreed two pathways for Helix marketing clearance: simultaneous with CardiAMP cell therapy approval or DeNovo via follow-on pre-submission.
- FDA raised no concerns on Helix safety data, device performance, or compatibility with general classes of agents.
- FDA's preferred route is simultaneous approval with CardiAMP cell therapy for heart failure.
- BioCardia aims to pursue both pathways to enhance development and commercial partnering.

## SEC filing metadata
- accession: 0001437749-26-015753
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774926015753/0001437749-26-015753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774926015753/bcda20260508_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-015753
- JSON: https://secwatch.observer/filing/0001437749-26-015753.json
- Plain text: https://secwatch.observer/filing/0001437749-26-015753.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.